Pharvaris released topline Phase 3 CHAPTER-3 results for deucrictibant XR 40 mg once daily in hereditary angioedema prophylaxis.
The primary endpoint was met with an 83% reduction in investigator-confirmed attacks versus placebo; 95% CI 72%-90%; p<0.0001.
The Type 1/2 subgroup showed an 87% reduction in attacks; all secondary efficacy endpoints were reported as statistically significant.
Quality of life improved, with AE-QoL difference versus placebo of -23.53 at Week 24; 95% CI -32.15 to -14.92; p<0.0001.
Safety was described as well tolerated; serious adverse events were 1.8% on deucrictibant XR versus 0% on placebo; no treatment-related serious events.
PHVS•
